Exploring how Erythropoietin affects blood cell development in humans
Investigating the Cell Type- and Receptor-Specific Effects of Erythropoietin that Mediate Erythropoiesis and Thrombopoiesis in Primary Human Hematopoietic Progenitor Cells
This study is looking at how a hormone called Erythropoietin (EPO) helps your body make red blood cells and platelets, which could lead to better treatments for people with anemia, especially those with kidney issues.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project ID | NIH-10995314 on NIH RePORTER |
What this research studies
This research investigates the specific effects of Erythropoietin (EPO) on different types of blood cell progenitors in humans, particularly focusing on how EPO influences the development of red blood cells and platelets. By examining human hematopoietic progenitor cells in a laboratory setting, the study aims to understand the signaling pathways activated by EPO and how these pathways affect cell survival and proliferation. This could lead to better treatments for patients suffering from anemia, especially those with chronic kidney disease, by optimizing EPO use and minimizing side effects.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults suffering from anemia due to chronic kidney disease.
Not a fit: Patients with anemia not related to chronic kidney disease or those who do not respond to EPO treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved therapies for anemia in patients with chronic kidney disease, reducing the need for blood transfusions and enhancing quality of life.
How similar studies have performed: Previous research has shown promising results in understanding the role of EPO in blood cell development, but this specific investigation into its effects on different progenitor cells is relatively novel.
Where this research is happening
Farmington, United States
- University of Connecticut Sch of Med/dnt — Farmington, United States (Active)
Researchers
- Principal investigator: Scanlon, Vanessa M. — University of Connecticut Sch of Med/dnt
- Study coordinator: Scanlon, Vanessa M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.